Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: Keys to success and roads to failure-Reference-Cited by-同舟云学术

Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: Keys to success and roads to failure

Published:2006 Issue:10 Volume:21 Page:1578-1594
ISSN:0885-3185
Container-title:Movement Disorders
language:en
Short-container-title:Mov Disord.

Author:

Fox Susan H.,Lang Anthony E.,Brotchie Jonathan M.

Publisher

Wiley

Subject

Clinical Neurology,Neurology

Reference152 articles.

1. A 2-DEOXYGLUCOSE STUDY OF THE EFFECTS OF DOPAMINE AGONISTS ON THE PARKINSONIAN PRIMATE BRAIN

2. Neural mechanisms mediating 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the monkey: Relative contributions of the striatopallidal and striatonigral pathways as suggested by 2-deoxyglucose uptake

3. The contribution of the MPTP-treated primate model to the development of new treatment strategies for Parkinson's disease

4. The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism

5. Relevance of the MPTP primate model in the study of dyskinesia priming mechanisms

Cited by 93 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Differential effects of opioid receptor antagonism on the anti-dyskinetic and anti-parkinsonian effects of sub-anesthetic ketamine treatment in a preclinical model;Neuropharmacology;2024-10

2. Antagonism of kappa opioid receptors accelerates the development of L-DOPA-induced dyskinesia in a preclinical model of moderate dopamine depletion;Brain Research;2023-12

3. Antagonism of kappa opioid receptors accelerates the development of L-DOPA-induced dyskinesia in a preclinical model of moderate dopamine depletion;2023-08-01

4. 7-Nitroindazole reduces L-DOPA-induced dyskinesias in non-human Parkinsonian primate;Open Biology;2023-05

5. A Randomized, Double‐Blind , Controlled Phase II Study of Foliglurax in Parkinson's Disease;Movement Disorders;2022-02-26